Review highlights advances in fluorescence imaging for tumors using organic small-molecule probes, suggesting improvements in biocompatibility and pharmacokinetics.
Over the past decade, near-infrared-II (NIR-II, 1000–1700 nm) fluorescence imaging has become a focal point in tumor imaging due to its advantages of low light scattering, weak biological autofluorescence, extraordinary penetration depth, high signal-to-background ratio, and micron-level high resolution. To date, a large number of NIR-II materials have been developed for tumor imaging. Among them, NIR-II organic small-molecule fluorophores have emerged as research hotspots owing to their distinctive advantages, such as superior optical properties, excellent controllability, favorable biocompatibility, and tunable pharmacokinetics. In this review, we summarize the latest progress in lNIR-II fluorescent probes based on organic small-molecule fluorophores for tumor imaging, focusing on their structural features, design principles of NIR-II fluorescent probes, and applications in tumor imaging. Finally, we will discuss the challenges, future prospects, and development directions of organic small-molecule fluorophores for NIR-II fluorescence imaging of tumors.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: